Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) shares passed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $8.26 and traded as low as $6.99. Astria Therapeutics shares last traded at $7.06, with a volume of 204,454 shares changing hands.
Analyst Upgrades and Downgrades
A number of brokerages have recently weighed in on ATXS. HC Wainwright reiterated a "buy" rating and issued a $16.00 target price on shares of Astria Therapeutics in a report on Thursday, January 23rd. Oppenheimer increased their price objective on Astria Therapeutics from $26.00 to $28.00 and gave the stock an "outperform" rating in a report on Thursday, November 14th. JMP Securities initiated coverage on Astria Therapeutics in a report on Friday, January 31st. They issued an "outperform" rating and a $26.00 price objective on the stock. Finally, Citizens Jmp upgraded Astria Therapeutics to a "strong-buy" rating in a report on Friday, January 31st. Six investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $25.67.
Check Out Our Latest Research Report on Astria Therapeutics
Astria Therapeutics Price Performance
The firm has a fifty day simple moving average of $8.01 and a 200 day simple moving average of $10.00. The company has a market cap of $384.29 million, a price-to-earnings ratio of -3.26 and a beta of 0.67.
Hedge Funds Weigh In On Astria Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. KLP Kapitalforvaltning AS acquired a new position in Astria Therapeutics during the fourth quarter valued at approximately $41,000. Tower Research Capital LLC TRC grew its holdings in Astria Therapeutics by 109.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company's stock valued at $47,000 after purchasing an additional 2,766 shares during the last quarter. BNP Paribas Financial Markets acquired a new position in Astria Therapeutics during the fourth quarter valued at approximately $50,000. Virtus ETF Advisers LLC acquired a new position in Astria Therapeutics during the fourth quarter valued at approximately $65,000. Finally, Quest Partners LLC grew its holdings in Astria Therapeutics by 180.8% during the third quarter. Quest Partners LLC now owns 9,004 shares of the biotechnology company's stock valued at $99,000 after purchasing an additional 5,798 shares during the last quarter. Institutional investors and hedge funds own 98.98% of the company's stock.
About Astria Therapeutics
(
Get Free Report)
Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.
Further Reading
Before you consider Astria Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astria Therapeutics wasn't on the list.
While Astria Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
